171 related articles for article (PubMed ID: 27789365)
1. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
[TBL] [Abstract][Full Text] [Related]
2. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
[TBL] [Abstract][Full Text] [Related]
3. Polysialic acid and pluronic F127 mixed polymeric micelles of docetaxel as new approach for enhanced antitumor efficacy.
Zhang T; Zhou S; Liu Y; Luo X; Di D; Song Y; Liu X; Deng Y
Drug Dev Ind Pharm; 2017 Nov; 43(11):1827-1835. PubMed ID: 28678638
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
[TBL] [Abstract][Full Text] [Related]
5. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
6. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
[TBL] [Abstract][Full Text] [Related]
7. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-octadecylamine conjugate for lung cancer treatment.
Luo X; Hu L; Zheng H; Liu M; Liu X; Li C; Qiu Q; Zhao Z; Cheng X; Lai C; Su Y; Deng Y; Song Y
Drug Deliv; 2018 Nov; 25(1):1200-1212. PubMed ID: 29791241
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration.
Dai J; Han S; Ju F; Han M; Xu L; Zhang R; Sun Y
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):860-873. PubMed ID: 29771149
[TBL] [Abstract][Full Text] [Related]
11. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
12. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity.
Luo X; Liu M; Hu L; Qiu Q; Liu X; Li C; Lu M; Liu Y; Zhang T; Zhou S; McClements DJ; Jia X; Deng Y; Song Y
Int J Pharm; 2018 Aug; 547(1-2):315-329. PubMed ID: 29886095
[TBL] [Abstract][Full Text] [Related]
14. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
15. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
16. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals.
Wu Y; Yang Y; Zhang FC; Wu C; Lü WL; Mei XG
J Liposome Res; 2011 Sep; 21(3):221-8. PubMed ID: 20929434
[TBL] [Abstract][Full Text] [Related]
18. Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method.
Gubernator J; Lipka D; Korycińska M; Kempińska K; Milczarek M; Wietrzyk J; Hrynyk R; Barnert S; Süss R; Kozubek A
PLoS One; 2014; 9(3):e91487. PubMed ID: 24621591
[TBL] [Abstract][Full Text] [Related]
19. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment.
Zhang CX; Zhao WY; Liu L; Ju RJ; Mu LM; Zhao Y; Zeng F; Xie HJ; Yan Y; Lu WL
Oncotarget; 2015 Oct; 6(32):32681-700. PubMed ID: 26418720
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
